iBio's (IBIO) Adds Patent in Bio-Defense Portfolio

iBio, Inc. (NYSE: IBIO) today announced issuance of a U.S. patent covering compositions of matter and methods of producing and formulating anthrax vaccines. The new patent is U.S. Patent 8,277,816 entitled "Bacillus Anthracis Antigens, Vaccine Compositions and Related Methods," and is based on an invention developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology, iBio's research collaborator.

"This new patent broadens protected uses of iBio's proprietary iBioLaunch™ platform and also expands the Company's portfolio of assets relevant to bio-defense applications, such as our successful preclinical vaccine for plague and a proprietary antibody for anthrax," said Terence Ryan, Ph.D., iBio's Chief Scientific Officer. "There should be significant interest in these opportunities from potential commercial collaborators focused on infectious disease and bio-defense markets."

Data published in peer-reviewed scientific journals previously demonstrated protection of non-human primates from anthrax spores by a proprietary antibody produced with the Company's proprietary iBioLaunch™ technology. Additional data confirmed protection of non-human primates from pneumonic plague by a proprietary vaccine incorporating iBioModulator technology produced via the iBioLaunch platform.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
• Mosaic sets pricing for tender offers on up to $1.4B in debt
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M